4.3 Review

Progressive multifocal leukoencephalopathy and JC Virus-related disease in modern neurology practice

Journal

MULTIPLE SCLEROSIS AND RELATED DISORDERS
Volume 3, Issue 4, Pages 419-430

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.msard.2014.01.005

Keywords

Progressive rritattifocal leukoencephalopathy; Multiple sclerosis; Natalizumab; JCV; JCV serology; PML-IRIS

Funding

  1. Genzyme
  2. National Multiple Sclerosis Society
  3. PML Consortium
  4. Biogenldec
  5. Millennium
  6. Genentech
  7. Amgen
  8. Eisai
  9. Novartis

Ask authors/readers for more resources

The natural history and clinical import of Progressive Multifocal Leukoencephalopathy has changed enormously in the last thirty years. After a resurgence of PML during the HIV/AIDS epidemic, advances in the treatment of multiple sclerosis created another group of 'at risk' patients. With a focus on issues pertaining to the multiple sclerosis patient population, this review covers pathophysiology of the JC virus, causes of PML, mechanisms by which natalizumab increases the risk of PML, determinants of PML risk in natalizumab-treated patients, risks of natalizumab discontinuation, PML prevention and surveillance, PML imaging features, PML diagnosis and stumbling blocks to making the diagnosis, PML and PML-Immune Reconstitution Inflammatory Syndrome (IRIS) treatment. (C) 2014 Elsevier B.V. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.3
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available